AbCellera Biologics (ABCL) is back on investors’ radar after early Phase 1 data for its lead program ABCL635 and a fresh quarterly earnings report that shows higher revenue and a smaller net loss.

The recent Phase 1 data for ABCL635 and the quarterly update appear to have coincided with a sharp acceleration in momentum, with the stock showing a 27.14% 7 day share price return, a 71.62% 90 day share price return, and a 163.96% 1 year total shareholder return. However, the 3 year and 5 year total shareholder returns are still down 23.53% and 80.62% respectively.

If you are watching how sentiment around drug development and AI enabled research platforms is shifting, it can be useful to broaden your watchlist with 34 healthcare AI stocks

With ABCL trading at $5.20 against an average analyst price target of $10.43 and recent gains already steep, the key question now is whether there is still an opportunity for investors to consider or if the market is already pricing in potential future growth.

Most Popular Narrative: 47.1% Undervalued

AbCellera’s most followed valuation story puts fair value at $9.83 per share, well above the recent $5.20 close, and leans heavily on its transition into a clinical stage biotech.

The initiation of Phase I clinical trials for ABCL635 and ABCL575, with promising differentiation factors such as a unique dosing regimen and improved safety profile for ABCL635, is expected to position the company to capture a significant market opportunity in an underserved area, potentially boosting future revenue.

Want to see what is sitting behind that fair value gap? Revenue ramp assumptions, margin shifts and a rich future earnings multiple all sit at the core of this narrative.

Result: Fair Value of $9.83 (UNDERVALUED)

However, this story can change quickly if high R&D spending keeps net losses elevated, or if ABCL635 struggles against existing menopause treatments in the clinic.

Another Angle on Valuation

The fair value story around $9.83 rests heavily on long term earnings assumptions. Looking at today’s P/S ratio of 20x gives a very different feel, because it sits well above both the US Life Sciences industry at 3.6x and peer average at 7.8x, while the fair ratio is just 0.3x. That kind of gap raises the question: is the market already running far ahead of fundamentals?

Next Steps

Feeling mixed after considering both the upside potential and the concerns raised so far? Review the data while it is still fresh in your mind and compare the 1 key reward and 2 important warning signs

Looking for more investment ideas?

If ABCL has your attention, do not stop here, the broader market is full of other stocks that could fit your goals just as well.

• Target potential mispricings by scanning companies that trade below their estimated worth using the 49 high quality undervalued stocks.
• Build a portfolio aimed at resilience and capital protection by filtering for 67 resilient stocks with low risk scores.
• Spot opportunities that the crowd may be overlooking by reviewing the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.